Dynamics of Endothelial Function Impairment in Patients with Initial Poor Compensation of Type 2 Diabetes Mellitus in Correction of Hypertension with Angiotensin II Receptor Antagonists during a year
The purpose of this study is to determine the dynamics of endothelial dysfunction intensity in patients with poor compensation of type 2 diabetes mellitus and hypertension treating with angiotensin II receptor antagonists during a year. It was shown that adequate hypoglycemic standard treatment allowed reduce the concentration of glycated hemoglobin level below 8 % in 48.6 % of patients and cause regression of microalbuminuria in 18.6 % of patients, but most patients had progressive endothelial dysfunction with increased concentrations of endothelin 1 and von Willebrand factor on 38.3 % (p < 0.05) and 27.8 % (p < 0.05), respectively versus baseline values, which was many times larger than control values. Hypoglycemic therapy in patients treated with angiotensin II receptor antagonists provided a reduction of glycated hemoglobin level to 7–8 % in 46.5 % of patients, and its normalization in 7.0 % of patients, followed by regression of microalbuminuria in 23.3 % of patients.
Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Rad Biol Med. 2003;34(12):1563-74.
Ceriello AA, Esposito K, Piconi L. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;13:1349-54.
Brenner BM, Cooper ME, Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-69.
Epstein M. Diabetes and hypertension: the bad companions. J Hypertension. 1997;15(2):55-62.
Torimoto K, Okada Y, Mori H, Tanaka Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;13:18-24.
Xu J, Zou MN. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;13:1266-86.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2017